Huichun Tai

Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung Cancer

Charles M. Rudin, Marissa Mattar, Elisa de Stanchina, 2018, Clinical Cancer Research.

Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers.

M. Ladanyi, A. Drilon, C. Rudin, 2018, Cancer discovery.

MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions

M. Ladanyi, A. Drilon, M. Kris, 2020, Clinical Cancer Research.

RET inhibition in novel patient-derived models of RET fusion- positive lung adenocarcinoma reveals a role for MYC upregulation

M. Ladanyi, A. Drilon, E. Cheng, 2020, Disease Models & Mechanisms.